Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-222 Triple Therapy in Genotype 1a HCV
NCT01581138Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lomibuvir in hepatitis C (HCV) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Sustained Viral Response at 12 Weeks. Started Jul 2012; status: completed.
02
Drugs
lomibuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01581138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01581138.